Vigilance of the effectiveness and safety of the VALERGEN vaccines in the treatment of asthma - PV-VALERGEN-Asthma

ational Center of Bioproducts (BIOCEN)0 个研究点目标入组 2,108 人开始时间: 2017年1月27日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Parallel. Purpose: Treatment

•1. Patients with confirmed diagnosis of intermittent asthma and mild to moderate persistent, associated with allergic sensitization to dust mites Dermatophagoides pteronyssinus, Dermatophagoides Siboney or Blomia tropicalis, indicating medical VALERGEN immunotherapy vaccines according manufacturer's instructions.
•2. Patients monosensitized and polysensitized.
•3. Both gender.
•4. Over 5 years of age.
•5. Patients with the ability to answer to interview questions or carer/tutor who can answer for patient.

•1. Patients without the capacity to answer to interview questions or carer / tutor who can answer for patient.
•2. Patients who can not be located for follow-up phone (with SLIT treatment)
•3. Patients unwilling to provide information.
•4. Patients with contraindications for the application of immunotherapy with VALERGEN vaccines, according to the manufacturer's instructions.
•5. Patients previously treated with immunotherapy with allergenic extracts in the two previous years.
•6. Patients who do not commit to regularly attend follow-up visits.

发起方

ational Center of Bioproducts (BIOCEN)